Belite Bio, Inc (BLTE)
NASDAQ: BLTE · Real-Time Price · USD
158.73
-4.33 (-2.66%)
At close: Apr 28, 2026, 4:00 PM EDT
158.73
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Belite Bio Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Belite Bio stock have an average target of 198, with a low estimate of 132 and a high estimate of 266. The average target predicts an increase of 24.74% from the current stock price of 158.73.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Belite Bio stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 3 |
| Buy | 2 | 3 | 4 | 4 | 4 | 4 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $200 | Strong Buy | Reiterates | $200 | +26.00% | Apr 22, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $200 | Strong Buy | Reiterates | $200 | +26.00% | Apr 13, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $185 → $200 | Strong Buy | Maintains | $185 → $200 | +26.00% | Mar 3, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $191 → $201 | Buy | Maintains | $191 → $201 | +26.63% | Mar 3, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $200 → $266 | Buy | Maintains | $200 → $266 | +67.58% | Mar 3, 2026 |
Financial Forecast
Revenue This Year
22.95M
Revenue Next Year
135.89M
from 22.95M
Increased by 492.11%
EPS This Year
-2.11
from -2.31
EPS Next Year
-2.38
from -2.11
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 189.0M | 202.4M | ||||||
| Avg | 23.0M | 135.9M | ||||||
| Low | n/a | 53.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 782.1% | ||||||
| Avg | - | 492.1% | ||||||
| Low | - | 132.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.98 | -0.08 | ||||||
| Avg | -2.11 | -2.38 | ||||||
| Low | -4.14 | -4.67 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.